Westlake Village-based Arcutis Biotherapeutics on Monday appointed Halley Gilbert to its board of directors. effective May 1.

Gilbert previously served as vice president of corporate development and chief administrative officer at Ironwood Pharmaceuticals in Boston. She oversaw corporate and business development, legal, compliance and government affairs.

She also specialized in mergers and acquisitions as well as securities law for Skadden Arps Slate Meagher & Flom in New York.

“She is an exceptionally talented board director and industry executive with over two decades of experience in legal, corporate and business development, compliance and government affairs,” Frank Watanabe, chief executive of Arcutis, said in a statement. “Her wealth of experience in building and growing successful commercial-stage biotechnology companies will be invaluable as we continue to advance Arcutis’ robust dermatology pipeline.”

Arcutis, a late-stage biopharma company focused on developing topical drugs for psoriasis and atopic dermatitis, went public in January. Shares of Arcutis (ARQT) closed Monday up 17 cents, or a fraction of a percent, to $29.78 on the Nasdaq.